BriaCell Therapeutics Corp. (BCTX): R&D Expense
$29.24M
Year ended 2026-07-31
+24.0%
3-year compound annual growth
+70.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2026-07-31 | $29.24M | +37.4% | 2026-10-28, From 2025-08-01 |
| 2025-07-31 | $21.27M | -21.7% | 2026-10-28, From 2024-08-01 |
| 2024-07-31 | $27.18M | +77.2% | 2025-10-16, From 2023-08-01 |
| 2023-07-31 | $15.34M | +91.2% | 2024-10-29, From 2022-08-01 |
| 2022-07-31 | $8.02M | +296.9% | 2023-10-25, From 2021-08-01 |
| 2021-07-31 | $2.02M | n/a | 2022-10-28, From 2020-08-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | 2026-07-31 | $29.24M | +37.4% |
| Immunic, Inc. (IMUX) | 2025-12-31 | $81.98M | +2.4% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $11.03M | -22.6% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $10.78M | +37.5% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $21.82M | +16.1% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $10.21M | -5.4% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $5.44M | -14.8% |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.89M | -10.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $6.31M | -29.3% |
Compare BCTX, IMUX, RNTX, KPRX side by side · Screen every company in Pharmaceutical Preparations ↗